437 related articles for article (PubMed ID: 35850495)
1. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.
Lee HA; Chang Y; Sung PS; Yoon EL; Lee HW; Yoo JJ; Lee YS; An J; Song DS; Cho YY; Kim SU; Kim YJ
Clin Mol Hepatol; 2022 Jul; 28(3):425-472. PubMed ID: 35850495
[TBL] [Abstract][Full Text] [Related]
2. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
[TBL] [Abstract][Full Text] [Related]
3. Chronic liver disease and oxidative stress - a narrative review.
Seen S
Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
[No Abstract] [Full Text] [Related]
4. [Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features].
Kalmykova ZA; Kononenko IV; Mayorov AY
Ter Arkh; 2019 Dec; 91(12):115-121. PubMed ID: 32598598
[TBL] [Abstract][Full Text] [Related]
5. REVIEW- Contemporary evidence on the dynamic role of probiotics in liver diseases.
Ahmed B; Rasul A; Tareen KZ; Hamid Akash MS; Muhammad SA; Irfan M; Abbas K; Qadir MI
Pak J Pharm Sci; 2019 Nov; 32(6):2765-2770. PubMed ID: 31969314
[TBL] [Abstract][Full Text] [Related]
6. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.
Angelico F
Drugs Context; 2024; 13():. PubMed ID: 38332944
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.
Setiawan VW; Stram DO; Porcel J; Lu SC; Le Marchand L; Noureddin M
Hepatology; 2016 Dec; 64(6):1969-1977. PubMed ID: 27301913
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease.
Tagger A; Ribero ML; Larghi A; Donato F; Zuin M; Chiesa R; Benetti G; Ramella G; Borzio M; Podda M
Am J Gastroenterol; 1999 Feb; 94(2):484-8. PubMed ID: 10022651
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
10. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
Federico A; Dallio M; Loguercio C
Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
[TBL] [Abstract][Full Text] [Related]
11. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
Vargas JI; Arrese M; Shah VH; Arab JP
Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
[TBL] [Abstract][Full Text] [Related]
12. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease: Advances in Diagnosis, Treatment and Clinical Practice. AASLD Liver Meeting, Boston, November 7-11, 2014].
Pár A
Orv Hetil; 2015 May; 156(21):869-72. PubMed ID: 26038995
[No Abstract] [Full Text] [Related]
14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
15. Natural History of Cirrhosis: Changing Trends in Etiology Over the Years.
Idilman R; Aydogan M; Oruncu MB; Kartal A; Elhan AH; Ellik Z; Gumussoy M; Er R; Ozercan M; Duman S; Toruner M; Cinar K; Soykan I; Beyler AR; Ozkan H
Dig Dis; 2021; 39(4):358-365. PubMed ID: 33142287
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Sahasrabuddhe VV; Gunja MZ; Graubard BI; Trabert B; Schwartz LM; Park Y; Hollenbeck AR; Freedman ND; McGlynn KA
J Natl Cancer Inst; 2012 Dec; 104(23):1808-14. PubMed ID: 23197492
[TBL] [Abstract][Full Text] [Related]
18. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.
Stauffer JK; Scarzello AJ; Jiang Q; Wiltrout RH
Hepatology; 2012 Oct; 56(4):1567-74. PubMed ID: 22378061
[TBL] [Abstract][Full Text] [Related]
19. Managing diabetes in patients with chronic liver disease.
Khan R; Foster GR; Chowdhury TA
Postgrad Med; 2012 Jul; 124(4):130-7. PubMed ID: 22913901
[TBL] [Abstract][Full Text] [Related]
20. Current status in the therapy of liver diseases.
Uhl P; Fricker G; Haberkorn U; Mier W
Int J Mol Sci; 2014 Apr; 15(5):7500-12. PubMed ID: 24786290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
